<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03748212</url>
  </required_header>
  <id_info>
    <org_study_id>188BE18024</org_study_id>
    <nct_id>NCT03748212</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Fed, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, fed, single dose, crossover study to evaluate the pharmacokinetic
      profiles and safety of CKD-385 in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of 52, following treatments are administered dosing in each period and
      wash-out period is a minimum of 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of Carvedilol</measure>
    <time_frame>Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs</time_frame>
    <description>Area under the plasma concentration of Carvedilol verses time curve from time zero to time of last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Carvedilol</measure>
    <time_frame>Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs</time_frame>
    <description>Maximum plasma concentration of Carvedilol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Carvedilol</measure>
    <time_frame>Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs</time_frame>
    <description>Area under the plasma concentration of Carvedilol versus time curve from time zero to time infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Carvedilol</measure>
    <time_frame>Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs</time_frame>
    <description>Time to maximum concentration of Carvedilol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Carvedilol</measure>
    <time_frame>Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs</time_frame>
    <description>Terminal elimination half-life of Carvedilol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Carvedilol</measure>
    <time_frame>Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs</time_frame>
    <description>Total body clearance of Carvedilol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Carvedilol</measure>
    <time_frame>Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs</time_frame>
    <description>Apparent volume of distribution of Carvedilol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D935 Cap. 1T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-385 Tab. 1T</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D935 Cap. 1T</intervention_name>
    <description>single oral administration under fed condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>D935</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-385 Tab. 1T</intervention_name>
    <description>single oral administration under fed condition</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>CKD-385</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A healthy adult aged over 19 at the time of screening

          2. Weight over 55, with BMI between 17.5kg/m² and 30.5kg/m²

          3. Subject who has no congenital or chronic disease within the last 3 years and no
             medical symptoms or signs as a result of medical examination

          4. Suitable subject who is determined at the time of screening by examiners according to
             the characteristics of the medicine such as hematology test, blood chemistry test,
             urine test, virus / bacteriological test, vital signs, electrocardiogram test

          5. Subject who signed the written consent form approved by Chonbuk National University
             Hospital IRB to participate in this study with full understanding of the purpose and
             contents of the examination prior to participation of the clinical trial

          6. Subject who has the ability and willingness to participate in the clinical trial

        Exclusion Criteria:

          1. Subject who has (or has histories of) clinically significant blood, kidney, endocrine,
             respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or
             allergic diseases(except for asymptomatic seasonal allergy at the time of
             administration) or evidence(except for simple dental history such as dental calculus,
             impacted tooth, wisdom tooth, etc.)

          2. Subject with a history of gastrointestinal disorders(esophageal achalasia or esophagus
             stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis
             surgery or hernia surgery or tooth extraction surgery) that may affect the absorption
             of drug

          3. Subject who shows the following values as a result of laboratory tests

             *ALT or AST &gt; 2 times upper limit of normal range

          4. Subject who has a history of regular alcohol consumption in excess of 210 g/week
             within 6 months of screening

          5. Subject who smokes more than one pack of cigarette a day within 6 months of screening

          6. Subject who took other clinical trial drugs or bioequivalence test drugs within 3
             months before the first administration of clinical trial drug

          7. Subject who conform to the specific items below

               -  systolic blood pressure less than 90 mmHg, greater than 140 mmHg or diastolic
                  blood pressure less than 60 mmHg or greater than 90 mmHg in a sitting position

               -  Severe bradycardia (less than 50 beats/minute)

          8. Subject who has significant alcohol abuse or drug abuse within a year of screening

          9. Subject who took drugs which are known as disturbing drug metabolism within 30 days
             prior to the first administration of clinical trial drug.

         10. Subject who uses any of other drugs, including over-the-counter medications and
             prescription medications within 10 days prior to first administration of clinical
             trial drug.

         11. Subject who donated whole blood within 2 months prior to first administration of
             clinical trial drug or blood components within 1 month prior to first administration
             of clinical trial drug

         12. Subject who is hypersensitive to the components of a clinical trial drug or clinical
             trial drug itself.

         13. Subject who does not consent to reliable contraception during the entire period of
             clinical trial and until 7th day of administration of clinical trial drug.

         14. Subject who is not able to consume high-fat meal provided during the clinical trial

         15. Any other subject who is decided by investigators to be ineligible in clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Ho Jang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung-Ho Jang</last_name>
    <phone>+82-63-259-3500</phone>
    <email>khjang@jbcp.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min-Gul Kim</last_name>
    <email>mgkim@jbcp.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-Ho Jang, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 18, 2018</study_first_submitted>
  <study_first_submitted_qc>November 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>December 27, 2018</last_update_submitted>
  <last_update_submitted_qc>December 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Chronic stable angina</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

